Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
06.10.2026 06:13
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
06.10.2026 06:13
Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
05.10.2026 12:00
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project
05.10.2026 12:00
Desktop study will use existing geological, geophysical and well data to assess natural hydrogen and helium potentialVANCOUVER, British Columbia, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has commissioned Lonquist Field Service (Canada), ULC (“Lonquist”) to conduct a desktop geological study to evaluate the potential for naturally occurring hydrogen and helium at its 100%-owned Robinsons Ri
Vertex (VRTX) or Regeneron (REGN)? Two Biotech Moats, Two Very Different Bets
03.10.2026 02:40
Biotech companies are strange businesses to think about in terms of competitive advantages. A software company can lock customers into an ecosystem for years. A manufacturer can have a cost advantage. A biotech company, meanwhile, can spend billions developing a drug only to see a competitor produce something better. That makes Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) […]
Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?
01.10.2026 19:17
Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial drug portfolio quickly but is still working toward consistent profitability.
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
29.09.2026 00:37
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]
Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?
29.09.2026 00:37
On September 22, Truist analyst Danielle Brill identified a “significant positive readthrough” for Maze Therapeutics, Inc. (NASDAQ:MAZE) following positive Phase 2 topline data from Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The data validates APOL1 inhibition in classic APOL1-mediated kidney disease (AMKD), supporting an addressable population of over 100,000 patients. Truist reiterated a Buy rating and $64 target […]
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
25.09.2026 04:23
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
24.09.2026 03:23
Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
24.09.2026 03:23
Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...
Vertex Posts Positive Phase II Data on Kidney Disease Drug
23.09.2026 16:08
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
CRISPR Therapeutics Traded Sideways and Down for 12 Months: One Wall Street Pro Expects 85% Gains Soon
23.09.2026 12:22
CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would embarrass the broader market, but the numbers tell a complicated story.
Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026: A $13.44 Billion Market by 2030 as Novartis, Vertex, CRISPR Therapeutics and Orchard Therapeutics Accelerate the Gene-Editing Race
23.09.2026 10:49
Boost ROI via rare-disease R&D, CRISPR therapies, scalable manufacturing, CDMO partnerships and regulatory incentives that accelerate approvals and commercialization. Autologous Hematopoietic Stem Cell Gene Therapy Market Autologous Hematopoietic Stem Cell Gene Therapy Market Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Autologous Hematopoietic Stem Cell Gene Therapy Market Global Report 2026" has been added to ResearchAndMarkets.com's offering. Autologous Hematopoietic Stem Cell Gene Therapy Mar
Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain
15.09.2026 11:30
BOSTON, September 15, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX® (suzetrigine), a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain in adults. Approved by the U.S. Food and Drug Administration (FDA) in January 2025, JOURNAVX marked the first new class of pain medicine in over 20 years — since then JOURNAVX has been prescribed to ove
Vertex Pharmaceuticals Highlights Catalyst-Rich Pipeline Beyond Cystic Fibrosis
12.09.2026 11:01
Vertex Pharmaceuticals (NASDAQ:VRTX) highlighted a series of upcoming clinical, regulatory and commercial catalysts across renal disease, pain management, cystic fibrosis and endocrinology during a Wells Fargo healthcare conference appearance. Susie Lisa, the company’s head of investor relations, s
Vertex Pharmaceuticals Maps Growth Beyond CF at Cantor Conference
12.09.2026 10:01
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined a broadening commercial and clinical strategy at the Cantor Global Healthcare Conference, highlighting its recent Crinetics acquisition, planned renal product launch efforts and upcoming pipeline milestones across kidney disease, pain, cystic fibrosis an
Set Yourself Up for a Strong 2027: 2 Pharmaceutical Stocks to Buy in September
11.09.2026 09:35
Both companies are approaching milestones that could light a fire under their stocks.
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
10.09.2026 04:17
Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
10.09.2026 04:17
Vertex Pharmaceuticals Incorporated (VRTX) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 4:30 PM EDTCompany ParticipantsConference Call...